Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Retained Earnings (2016 - 2025)

Editas Medicine (EDIT) has disclosed Retained Earnings for 11 consecutive years, with -$1.6 billion as the latest value for Q2 2025.

  • Quarterly Retained Earnings fell 14.13% to -$1.6 billion in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$1.6 billion through Jun 2025, down 14.13% year-over-year, with the annual reading at -$1.5 billion for FY2024, 19.25% down from the prior year.
  • Retained Earnings for Q2 2025 was -$1.6 billion at Editas Medicine, down from $88000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $522000.0 in Q3 2024, with the low at -$1.6 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$652.2 million, with a median of -$769.1 million recorded in 2021.
  • The sharpest move saw Retained Earnings crashed 1700525.0% in 2021, then skyrocketed 126.99% in 2025.
  • Over 5 years, Retained Earnings stood at -$493000.0 in 2021, then crashed by 630.43% to -$3.6 million in 2022, then crashed by 34094.67% to -$1.2 billion in 2023, then dropped by 19.25% to -$1.5 billion in 2024, then fell by 8.81% to -$1.6 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.6 billion, $88000.0, and -$1.5 billion for Q2 2025, Q1 2025, and Q4 2024 respectively.